Marimed (MRMD) Net Income towards Common Stockholders (2011 - 2026)
Marimed (MRMD) posted quarterly Net Income towards Common Stockholders of -$3.8 million for Q1 2026, up 31.25% year-over-year from -$2.9 million in Q1 2025, and up 18.83% quarter-over-quarter from -$4.6 million in Q4 2025.
Marimed (MRMD) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Marimed (MRMD) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$3.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 31.25% year-over-year to -$3.8 million; the TTM figure through Mar 2026 stood at -$12.6 million (up 22.92% YoY), while the FY2025 annual figure was -$14.5 million, down 16.3% from the prior year.
- Net Income towards Common Stockholders improved to -$3.8 million in Q1 2026 per MRMD's latest filing, from -$4.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $4.7 million in Q4 2022 and bottomed at -$10.1 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$1.9 million across 5 years, with a median of -$1.3 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 174.13% — and 2025, when it plunged 324.07%.
- Marimed's Net Income towards Common Stockholders stood at $4.7 million in 2022, then plunged by 313.5% to -$10.1 million in 2023, then increased by 18.49% to -$8.3 million in 2024, then jumped by 43.84% to -$4.6 million in 2025, then climbed by 18.83% to -$3.8 million in 2026.
- Business Quant data shows MRMD's Net Income towards Common Stockholders at -$3.8 million in Q1 2026, -$4.6 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Marimed | 27.77 Mn | 19.33 Mn | 16.23 Mn | -3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.57 Mn |
| Mar 31, 2026 | -3.77 Mn |
| Dec 31, 2025 | -4.64 Mn |
| Sep 30, 2025 | -2.94 Mn |
| Jun 30, 2025 | -1.27 Mn |
| Mar 31, 2025 | -5.48 Mn |
| Dec 31, 2024 | -8.26 Mn |
| Sep 30, 2024 | -990,000.00 |
| Jun 30, 2024 | -1.64 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -10.14 Mn |
| Sep 30, 2023 | -4.27 Mn |
| Jun 30, 2023 | -935,000.00 |
| Mar 31, 2023 | -664,000.00 |
| Dec 31, 2022 | 4.75 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 4.24 Mn |
| Dec 31, 2021 | -6.41 Mn |
| Sep 30, 2021 | 2.12 Mn |